Consensus statement: the role of prostate-specific antigen in managing the patient with benign prostatic hyperplasia.
Bartsch
G
G
Department of Urology, University of Innsbruck, Austria. georg.bartsch@uibk.ac.at
Fitzpatrick
J M
JM
Schalken
J A
JA
Isaacs
J
J
Nordling
J
J
Roehrborn
C G
CG
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000627:therapeutic use; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D032921:Consensus; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology*; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000473:pathology / Q000628:therapy*; D012307:Risk Factors
D000317:Adrenergic alpha-Antagonists; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase; D017430:Prostate-Specific Antigen